About Us

HDL Therapeutics is a commercial-stage biotechnology company with an FDA approved therapy for reducing coronary atheroma in a rare cardiovascular disease.

Our Culture

Our aspirations encourage us to view patient treatment for what it can be, not just for what it is today. 
Our unconventional mindset drives us to seek disruptive scientific breakthroughs to a better patient outcome. 
Our “can-do” attitude inspires us to create real solutions to the health challenges facing our patients. 

Disrupting the Industry

HDL Therapeutics represents the union of some of the top talent in the pharmaceutical, biotechnology, and medical device industries. Co-founders Michael Matin, CEO and Chairman of the Board, and Dr. Bryan Brewer, Chief Scientific Officer, bring decades of experience with large pharmaceutical organizations, blockbuster product launches, and breakthrough research. 

Vision / Mission

We are working on the cutting edge of science with future therapies for cardiovascular, neurodegenerative, autoimmune, viral and peripheral vascular diseases. 

Our mission is to fill a critical gap in treatment options for patients with severe atherosclerotic disease through our breakthrough therapy that harness the power of HDL to reverse—rather than just manage—atherosclerosis.

Vision / Mission

We are working on the cutting edge of science with future therapies for cardiovascular, neurodegenerative, autoimmune, viral and peripheral vascular diseases. 
Our mission is to fill a critical gap in treatment options for patients with severe atherosclerotic disease through our breakthrough therapy that harness the power of HDL to reverse—rather than just manage—atherosclerosis.